Stock TEVJF TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Teva Pharmaceutical Industries Limited Stock OTC Markets

Equities

TEVJF

IL0006290147

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 15:59:37 2024-06-12 EDT 		5-day change 1st Jan Change
18 USD +7.78% Intraday chart for Teva Pharmaceutical Industries Limited +7.78% +108.82%
06-14 Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... Our Logo
06-14 Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym MT

Financials

Sales 2024 * 16B 21.98B Sales 2025 * 16.62B 22.83B Capitalization 19.44B 26.69B
Net income 2024 * 809M 1.11B Net income 2025 * 1.38B 1.89B EV / Sales 2024 * 2.15 x
Net Debt 2024 * 14.98B 20.58B Net Debt 2025 * 12.44B 17.09B EV / Sales 2025 * 1.92 x
P/E ratio 2024 *
17.8 x
P/E ratio 2025 *
12.3 x
Employees 35,737
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.92%
More Fundamentals * Assessed data

Chart Teva Pharmaceutical Industries Limited

Dynamic Chart

Latest news about Teva Pharmaceutical Industries Limited

Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... Our Logo
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym MT
Transcript : Teva Pharmaceutical Industries Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating MT
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill MT
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day) CI
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S CI
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 CI
Transcript : Teva Pharmaceutical Industries Limited Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT
More news

Latest transcript on Teva Pharmaceutical Industries Limited

Logo Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
More transcripts

Analyst Recommendations on Teva Pharmaceutical Industries Limited

Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing MT
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
More recommendations

Press releases Teva Pharmaceutical Industries Limited

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference BU
Teva Pharmaceuticals - New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY Extended-Release Injectable Suspension from Invega Sustenna AQ
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) BU
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 BU
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) BU
More press releases

News in other languages on Teva Pharmaceutical Industries Limited

En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor
FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA
More news

Quotes and Performance

1 day+7.78%
1 week+7.78%
Current month+20.64%
1 month+53.19%
3 months+36.36%
6 months+108.82%
Current year+108.82%
More quotes

Highs and lows

1 week
16.87
Extreme 16.8675
18.00
1 month
14.92
Extreme 14.92
18.00
Current year
10.58
Extreme 10.58
18.00
1 year
7.03
Extreme 7.03
18.00
3 years
0.00
Extreme 0
18.00
5 years
0.00
Extreme 0
18.00
10 years
0.00
Extreme 0
69.24
More quotes

Managers and Directors - Teva Pharmaceutical Industries Limited

Managers TitleAgeSince
Richard Francis CEO
 Chief Executive Officer 55 22-12-31
Eli Kalif DFI
 Director of Finance/CFO 51 19-12-21
Kathleen Veit CMP
 Compliance Officer - 09-12-31
Members of the board TitleAgeSince
Gerald Lieberman BRD
 Director/Board Member 77 15-08-31
Janet Vergis BRD
 Director/Board Member 59 20-06-08
Sol Barer CHM
 Chairman 76 14-12-31
More insiders

Quotes

Date Price Change Volume
24-06-12 18 +7.78% 857

Delayed Quote OTC Markets, June 12, 2024 at 03:59 pm

More quotes

Company Profile

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
2024-08-06 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
17.16 USD
Average target price
18.34 USD
Spread / Average Target
+6.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 225B
NOVARTIS AG Stock Novartis AG
+11.95% 218B
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
PFIZER, INC. Stock Pfizer, Inc.
-4.38% 156B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. TEVJF Stock